# BioInvent Reports 10.3-Month Median PFS for BI-1808 Plus Pembrolizumab in Ovarian Cancer

> BioInvent published Phase 1/2a BI-1808 plus pembrolizumab data showing a 10.3-month iRECIST median PFS and set a randomized triplet study for Q1 2027.

- Published: 2026-10-18T23:02:31+00:00
- Section: Research & Clinical Trials
- Author: News Desk
- URL: https://newsforagent.com/news/2026-10-18/bioinvent-bi-1808-prroc-triplet-study
- Source: [TradingView](https://www.tradingview.com/news/tradingview:5ad94c264e8eb:0-bioinvent-international-ab-binv-posts-bi-1808-prroc-data-plans-randomized-triplet-study/)

## Key takeaways

- BioInvent published Phase 1/2a data for BI-1808 plus pembrolizumab in platinum-resistant recurrent ovarian cancer, with an iRECIST median PFS of 10.3 months versus 4.2 months by RECIST.
- The company plans to start Part C, a randomized triplet with paclitaxel with or without bevacizumab, in the first quarter of 2027, with first data expected in the second half of 2027.
- BioInvent is a clinical-stage Swedish biotech founded in 1988, headquartered in Lund, that develops immuno-oncology antibodies and is listed on Nasdaq Stockholm under BINV.

[BioInvent](https://akta.pro/company-profiles/00055qj/bioinvent) published an abstract ahead of ESMO with previously communicated Phase 1/2a data for BI-1808 plus pembrolizumab in platinum-resistant recurrent ovarian cancer, showing an iRECIST median progression-free survival of 10.3 months versus 4.2 months by RECIST, and plans to start a randomized triplet study with paclitaxel in the first quarter of 2027. [TradingView](https://www.tradingview.com/news/tradingview:5ad94c264e8eb:0-bioinvent-international-ab-binv-posts-bi-1808-prroc-data-plans-randomized-triplet-study/) carried the report.

## BioInvent's BI-1808 Data and Triplet Plan

The abstract reports an iRECIST median PFS of 10.3 months and a RECIST median PFS of 4.2 months for BI-1808 plus pembrolizumab in PRROC. Enrollment in the combination cohort is completed. BioInvent plans to start Part C, a randomized triplet with paclitaxel, with or without bevacizumab, in the first quarter of 2027, with first data expected in the second half of 2027, subject to enrollment. The company cited preclinical synergy with paclitaxel as the rationale for the triplet.

BioInvent is a clinical-stage Swedish biotech that discovers and develops immuno-oncology antibodies for cancer therapy, serving pharmaceutical partners through licensing, co-development, clinical supply agreements and contract GMP manufacturing, according to akta.pro [company records](https://akta.pro/company-data). The company was founded in 1988 and is headquartered in Lund, with 101 to 250 employees. Its shares trade on Nasdaq Stockholm under BINV. Net sales were SEK 226.5 million in 2025, up from SEK 44.7 million in 2024, and its net loss was SEK -332.9 million in 2025, reduced from SEK -429.4 million in 2024, the same records show.

## BioInvent's Path to the Randomized Triplet

On August 7, 2026, the FDA granted fast track designation to BI-1808, a first-in-class anti-TNFR2 antibody, for ovarian cancer treatment in combination with pembrolizumab, BioPharm International reported. In July 2026, BioInvent's abstract for recurrent platinum-resistant ovarian cancer was accepted for a poster at ESMO 2026 in Madrid, with the combination raising the response rate to 24% from 8% with pembrolizumab alone, according to Morningstar. BioInvent published a preclinical manuscript in Cancer Research in August 2026 detailing the mechanism of action and antitumor efficacy of BI-1808 and BI-1910, BioSpace reported.

## What Comes Next for BioInvent

BioInvent plans to start Part C in the first quarter of 2027, with first data expected in the second half of 2027, subject to enrollment. The company said updated data is expected before year-end 2026.

## Companies in this story

- [BioInvent company profile](https://akta.pro/company-profiles/00055qj/bioinvent) · website: https://www.bioinvent.com

---
News for Agent · https://newsforagent.com/llms.txt